Cargando…

EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice

Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase mediating trimethylation of H3K27, which represses gene expression and is critical to immune regulation. Inhibition of EZH2 is proved to have the potential of treating many diseases. However, whether inhibition of EZH2 affect...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Lingling, Jiang, Xiaoyue, Qi, Chaojun, Zhang, Chunyan, Qu, Bo, Shen, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044841/
https://www.ncbi.nlm.nih.gov/pubmed/33868295
http://dx.doi.org/10.3389/fimmu.2021.653989
_version_ 1783678576000761856
author Wu, Lingling
Jiang, Xiaoyue
Qi, Chaojun
Zhang, Chunyan
Qu, Bo
Shen, Nan
author_facet Wu, Lingling
Jiang, Xiaoyue
Qi, Chaojun
Zhang, Chunyan
Qu, Bo
Shen, Nan
author_sort Wu, Lingling
collection PubMed
description Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase mediating trimethylation of H3K27, which represses gene expression and is critical to immune regulation. Inhibition of EZH2 is proved to have the potential of treating many diseases. However, whether inhibition of EZH2 affects type I interferon (IFN-I) signaling pathway, the abnormality of which is an important pathogenic mechanism for SLE, is still elusive. Here, we report, unexpectedly, a positive regulatory function of EZH2 in IFN-I signaling pathway, which contributes to the overactivation of IFN-I signaling pathway in SLE. We show that the expression of EZH2 was upregulated and positively correlated with the overexpression of interferon stimulated genes (ISGs) in both peripheral blood mononuclear cells and renal tissues of SLE patients. In vitro inhibition of EZH2 by either siRNAs or chemical inhibitors reduced the phosphorylation of STAT1 and the induction of ISGs stimulated by IFN-I. Additionally, inhibition of EZH2 interfered with the in vivo and ex vivo activation of IFN-I signaling pathway elicited by intravenous injection of adenovirus vector expressing mouse IFN-α5 and exogeneous stimulation with IFN-α, respectively. We evaluated the therapeutic effects of EZH2 inhibitor in NZB/NZW F1 mice which depend on IFN-I signaling pathway for the lupus-like disease development. Administration of EZH2 inhibitor prolonged the survival, reduced the levels of anti-dsDNA autoantibodies, and improved lupus nephritis of the mice. What’s more, EZH2 inhibitor attenuated the expression of ISGs in the kidneys of these mice. In summary, we show that excessive EZH2 contributes to the overactivation of IFN-I signaling pathway in SLE. EZH2 inhibitor has the potential to inhibit IFN-I signaling pathway and alleviate lupus nephritis. Additionally, diverse disease driving pathways exist among systemic lupus erythematosus (SLE) patient, and even in the same patients. Common regulators of different pathogenic pathways can be multivalent therapeutic targets. Together with previous studies showing EZH2 is involved in T-cell and B-cell mediated immune responses, EZH2 could be a potent multivalent therapeutic target for SLE.
format Online
Article
Text
id pubmed-8044841
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80448412021-04-15 EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice Wu, Lingling Jiang, Xiaoyue Qi, Chaojun Zhang, Chunyan Qu, Bo Shen, Nan Front Immunol Immunology Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase mediating trimethylation of H3K27, which represses gene expression and is critical to immune regulation. Inhibition of EZH2 is proved to have the potential of treating many diseases. However, whether inhibition of EZH2 affects type I interferon (IFN-I) signaling pathway, the abnormality of which is an important pathogenic mechanism for SLE, is still elusive. Here, we report, unexpectedly, a positive regulatory function of EZH2 in IFN-I signaling pathway, which contributes to the overactivation of IFN-I signaling pathway in SLE. We show that the expression of EZH2 was upregulated and positively correlated with the overexpression of interferon stimulated genes (ISGs) in both peripheral blood mononuclear cells and renal tissues of SLE patients. In vitro inhibition of EZH2 by either siRNAs or chemical inhibitors reduced the phosphorylation of STAT1 and the induction of ISGs stimulated by IFN-I. Additionally, inhibition of EZH2 interfered with the in vivo and ex vivo activation of IFN-I signaling pathway elicited by intravenous injection of adenovirus vector expressing mouse IFN-α5 and exogeneous stimulation with IFN-α, respectively. We evaluated the therapeutic effects of EZH2 inhibitor in NZB/NZW F1 mice which depend on IFN-I signaling pathway for the lupus-like disease development. Administration of EZH2 inhibitor prolonged the survival, reduced the levels of anti-dsDNA autoantibodies, and improved lupus nephritis of the mice. What’s more, EZH2 inhibitor attenuated the expression of ISGs in the kidneys of these mice. In summary, we show that excessive EZH2 contributes to the overactivation of IFN-I signaling pathway in SLE. EZH2 inhibitor has the potential to inhibit IFN-I signaling pathway and alleviate lupus nephritis. Additionally, diverse disease driving pathways exist among systemic lupus erythematosus (SLE) patient, and even in the same patients. Common regulators of different pathogenic pathways can be multivalent therapeutic targets. Together with previous studies showing EZH2 is involved in T-cell and B-cell mediated immune responses, EZH2 could be a potent multivalent therapeutic target for SLE. Frontiers Media S.A. 2021-03-26 /pmc/articles/PMC8044841/ /pubmed/33868295 http://dx.doi.org/10.3389/fimmu.2021.653989 Text en Copyright © 2021 Wu, Jiang, Qi, Zhang, Qu and Shen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wu, Lingling
Jiang, Xiaoyue
Qi, Chaojun
Zhang, Chunyan
Qu, Bo
Shen, Nan
EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice
title EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice
title_full EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice
title_fullStr EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice
title_full_unstemmed EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice
title_short EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice
title_sort ezh2 inhibition interferes with the activation of type i interferon signaling pathway and ameliorates lupus nephritis in nzb/nzw f1 mice
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044841/
https://www.ncbi.nlm.nih.gov/pubmed/33868295
http://dx.doi.org/10.3389/fimmu.2021.653989
work_keys_str_mv AT wulingling ezh2inhibitioninterfereswiththeactivationoftypeiinterferonsignalingpathwayandameliorateslupusnephritisinnzbnzwf1mice
AT jiangxiaoyue ezh2inhibitioninterfereswiththeactivationoftypeiinterferonsignalingpathwayandameliorateslupusnephritisinnzbnzwf1mice
AT qichaojun ezh2inhibitioninterfereswiththeactivationoftypeiinterferonsignalingpathwayandameliorateslupusnephritisinnzbnzwf1mice
AT zhangchunyan ezh2inhibitioninterfereswiththeactivationoftypeiinterferonsignalingpathwayandameliorateslupusnephritisinnzbnzwf1mice
AT qubo ezh2inhibitioninterfereswiththeactivationoftypeiinterferonsignalingpathwayandameliorateslupusnephritisinnzbnzwf1mice
AT shennan ezh2inhibitioninterfereswiththeactivationoftypeiinterferonsignalingpathwayandameliorateslupusnephritisinnzbnzwf1mice